- America's Newsroom
- April 6th, 2020
Atossa Therapeutics leading clinical trial that may improve pulmonary function in COVID-19 patients
Dr. Steven Quay, physician scientist and Atossa Therapeutics CEO, joins ‘America’s Newsroom’ to explain.
Atossa Therapeutics leading clinical trial that may improve pulmonary function in COVID-19 patients
Dr. Steven Quay, physician scientist and Atossa Therapeutics CEO, joins ‘America’s Newsroom’ to explain.
He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.
His current passion is the prevention of the two million yearly breast cancer cases worldwide.
(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies
Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.
Join Dr. Quay’s ElevatorMedicine™ and get FREE, QUICK TIPS for better living, health, and wellness that take less time than riding an elevator!
